API | polatuzumab vedotin

polatuzumab vedotin (Polivy) Report issue

Biologics mAb ADC Orphan Drug ^FDA Approved ^FDA Accelerated Approval ^FDA

AACT ChEMBL DrugBank MeSH

Active Ingredient History

NOW

Polatuzumab vedotin, sold under the brand name Polivy, is a CD79b-directed antibody-drug conjugate medication used for the treatment of diffuse large B-cell lymphoma (cancer). It was developed by the Genentech subsidiary of Roche. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules:

None

None

polatuzumab vedotin

pinatuzumab vedotin

More Chemistry

Pharmacology

Mechanisms of Action:
- B-cell antigen receptor complex-associated protein beta chain (Homo sapiens) ^UniProt
- B-cell receptor CD22 (Homo sapiens) ^UniProt
Multi-specific: No
Payload: Monomethylauristatin E
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

Drug Pricing (per unit)

United States

$2454.0600 - $15000.0000

More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

acd22-vcmmae | acd79b-vcmmae | dcds-4501a | dcdt2980s | dcdt-2980s | fcu-2703 | fcu-2711 | pinatuzumab vedotin | polatuzumab vedotin | rg-7593 | rg-7596 | ro-5541072-000 | ro-5541077-000

Organizations (42)

Research & Development (42)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (14)

Approved Indications (1)

Lymphoma, Large B-Cell, Diffuse (approved 2019)

Experimental Indications - Clinical Trial Phases 1-4 (14)

Burkitt Lymphoma (Phase 1/Phase 2)

Hodgkin Disease (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, B-Cell, Marginal Zone (Phase 2)

Lymphoma, Follicular (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 3)

Lymphoma, Large-Cell, Immunoblastic (Phase 3)

Lymphoma, Mantle-Cell (Phase 2)

Lymphoma, Non-Hodgkin (Phase 3)

Lymphoma, Primary Cutaneous Anaplastic Large Cell (Phase 2)

Lymphoma, T-Cell (Phase 1)

Transplantation (Phase 1/Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 51
# of Trial Organizations: 42

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue